High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party

Saad Akhtar, Silvia Montoto, Ariane Boumendil, Herve Finel, T. Masszi, Pavel Jindra, Damir Nemet, Stephan Fuhrmann, Yves Beguin, Luca Castagna, Felicetto Ferrara, Saveria Capria, Ram Malladi, Jose Maria Moraleda, Adrian Bloor, Hervé Ghesquières, Julia Meissner, Anna Sureda, Peter Dreger

Research output: Article

4 Citations (Scopus)

Abstract

Whilst autologous stem cell transplantation (auto-SCT) is considered standard of care for relapsed/refractory classical Hodgkin lymphoma, the role of auto-SCT in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto-SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed/refractory NLPHL who underwent first auto-SCT with disease chemosensitive to salvage therapy. NLPHL transformed to diffuse large B cell lymphoma were excluded. Sixty patients (83% male; median age 40 years) met the eligibility criteria. The median time between diagnosis and transplant was 21 months (IQR 13–58), and the median number of prior treatment lines was 2 (range 1–5), including rituximab in 63% of the patients. At auto-SCT, 62% of the patients were in complete remission (CR) and 38% in partial remission. Seventy-two percent of the patients received BEAM as high-dose therapy. With a median follow-up of 56 months (range 3–105), 5-year progression-free and overall survival (OS) were 66% and 87%, respectively. Univariate comparisons considering age, time from diagnosis to transplant, prior chemotherapy lines, and prior rituximab use failed to identify significant predictors for any survival endpoint except for being in CR at the time of auto-SCT (vs PR, P =.049) for OS. Auto-SCT in patients with relapsed/refractory NLPHL who are sensitive to salvage therapy gives excellent disease control and long-term survival independent of the time interval between diagnosis and transplant.

Original languageEnglish
Pages (from-to)40-46
Number of pages7
JournalAmerican Journal of Hematology
Volume93
Issue number1
DOIs
Publication statusPublished - jan. 1 2018

Fingerprint

Stem Cell Transplantation
Hodgkin Disease
Lymphoma
Retrospective Studies
Transplantation
Bone Marrow
Drug Therapy
Salvage Therapy
Transplants
Survival
Lymphoma, Large B-Cell, Diffuse
Standard of Care
Disease-Free Survival
Registries
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma : A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. / Akhtar, Saad; Montoto, Silvia; Boumendil, Ariane; Finel, Herve; Masszi, T.; Jindra, Pavel; Nemet, Damir; Fuhrmann, Stephan; Beguin, Yves; Castagna, Luca; Ferrara, Felicetto; Capria, Saveria; Malladi, Ram; Moraleda, Jose Maria; Bloor, Adrian; Ghesquières, Hervé; Meissner, Julia; Sureda, Anna; Dreger, Peter.

In: American Journal of Hematology, Vol. 93, No. 1, 01.01.2018, p. 40-46.

Research output: Article

Akhtar, S, Montoto, S, Boumendil, A, Finel, H, Masszi, T, Jindra, P, Nemet, D, Fuhrmann, S, Beguin, Y, Castagna, L, Ferrara, F, Capria, S, Malladi, R, Moraleda, JM, Bloor, A, Ghesquières, H, Meissner, J, Sureda, A & Dreger, P 2018, 'High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party', American Journal of Hematology, vol. 93, no. 1, pp. 40-46. https://doi.org/10.1002/ajh.24927
Akhtar, Saad ; Montoto, Silvia ; Boumendil, Ariane ; Finel, Herve ; Masszi, T. ; Jindra, Pavel ; Nemet, Damir ; Fuhrmann, Stephan ; Beguin, Yves ; Castagna, Luca ; Ferrara, Felicetto ; Capria, Saveria ; Malladi, Ram ; Moraleda, Jose Maria ; Bloor, Adrian ; Ghesquières, Hervé ; Meissner, Julia ; Sureda, Anna ; Dreger, Peter. / High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma : A retrospective study by the European society for blood and marrow transplantation-lymphoma working party. In: American Journal of Hematology. 2018 ; Vol. 93, No. 1. pp. 40-46.
@article{ae4571bf2fdb4bbebd86330fb92998d4,
title = "High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party",
abstract = "Whilst autologous stem cell transplantation (auto-SCT) is considered standard of care for relapsed/refractory classical Hodgkin lymphoma, the role of auto-SCT in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto-SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed/refractory NLPHL who underwent first auto-SCT with disease chemosensitive to salvage therapy. NLPHL transformed to diffuse large B cell lymphoma were excluded. Sixty patients (83{\%} male; median age 40 years) met the eligibility criteria. The median time between diagnosis and transplant was 21 months (IQR 13–58), and the median number of prior treatment lines was 2 (range 1–5), including rituximab in 63{\%} of the patients. At auto-SCT, 62{\%} of the patients were in complete remission (CR) and 38{\%} in partial remission. Seventy-two percent of the patients received BEAM as high-dose therapy. With a median follow-up of 56 months (range 3–105), 5-year progression-free and overall survival (OS) were 66{\%} and 87{\%}, respectively. Univariate comparisons considering age, time from diagnosis to transplant, prior chemotherapy lines, and prior rituximab use failed to identify significant predictors for any survival endpoint except for being in CR at the time of auto-SCT (vs PR, P =.049) for OS. Auto-SCT in patients with relapsed/refractory NLPHL who are sensitive to salvage therapy gives excellent disease control and long-term survival independent of the time interval between diagnosis and transplant.",
author = "Saad Akhtar and Silvia Montoto and Ariane Boumendil and Herve Finel and T. Masszi and Pavel Jindra and Damir Nemet and Stephan Fuhrmann and Yves Beguin and Luca Castagna and Felicetto Ferrara and Saveria Capria and Ram Malladi and Moraleda, {Jose Maria} and Adrian Bloor and Herv{\'e} Ghesqui{\`e}res and Julia Meissner and Anna Sureda and Peter Dreger",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ajh.24927",
language = "English",
volume = "93",
pages = "40--46",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma

T2 - A retrospective study by the European society for blood and marrow transplantation-lymphoma working party

AU - Akhtar, Saad

AU - Montoto, Silvia

AU - Boumendil, Ariane

AU - Finel, Herve

AU - Masszi, T.

AU - Jindra, Pavel

AU - Nemet, Damir

AU - Fuhrmann, Stephan

AU - Beguin, Yves

AU - Castagna, Luca

AU - Ferrara, Felicetto

AU - Capria, Saveria

AU - Malladi, Ram

AU - Moraleda, Jose Maria

AU - Bloor, Adrian

AU - Ghesquières, Hervé

AU - Meissner, Julia

AU - Sureda, Anna

AU - Dreger, Peter

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Whilst autologous stem cell transplantation (auto-SCT) is considered standard of care for relapsed/refractory classical Hodgkin lymphoma, the role of auto-SCT in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto-SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed/refractory NLPHL who underwent first auto-SCT with disease chemosensitive to salvage therapy. NLPHL transformed to diffuse large B cell lymphoma were excluded. Sixty patients (83% male; median age 40 years) met the eligibility criteria. The median time between diagnosis and transplant was 21 months (IQR 13–58), and the median number of prior treatment lines was 2 (range 1–5), including rituximab in 63% of the patients. At auto-SCT, 62% of the patients were in complete remission (CR) and 38% in partial remission. Seventy-two percent of the patients received BEAM as high-dose therapy. With a median follow-up of 56 months (range 3–105), 5-year progression-free and overall survival (OS) were 66% and 87%, respectively. Univariate comparisons considering age, time from diagnosis to transplant, prior chemotherapy lines, and prior rituximab use failed to identify significant predictors for any survival endpoint except for being in CR at the time of auto-SCT (vs PR, P =.049) for OS. Auto-SCT in patients with relapsed/refractory NLPHL who are sensitive to salvage therapy gives excellent disease control and long-term survival independent of the time interval between diagnosis and transplant.

AB - Whilst autologous stem cell transplantation (auto-SCT) is considered standard of care for relapsed/refractory classical Hodgkin lymphoma, the role of auto-SCT in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto-SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed/refractory NLPHL who underwent first auto-SCT with disease chemosensitive to salvage therapy. NLPHL transformed to diffuse large B cell lymphoma were excluded. Sixty patients (83% male; median age 40 years) met the eligibility criteria. The median time between diagnosis and transplant was 21 months (IQR 13–58), and the median number of prior treatment lines was 2 (range 1–5), including rituximab in 63% of the patients. At auto-SCT, 62% of the patients were in complete remission (CR) and 38% in partial remission. Seventy-two percent of the patients received BEAM as high-dose therapy. With a median follow-up of 56 months (range 3–105), 5-year progression-free and overall survival (OS) were 66% and 87%, respectively. Univariate comparisons considering age, time from diagnosis to transplant, prior chemotherapy lines, and prior rituximab use failed to identify significant predictors for any survival endpoint except for being in CR at the time of auto-SCT (vs PR, P =.049) for OS. Auto-SCT in patients with relapsed/refractory NLPHL who are sensitive to salvage therapy gives excellent disease control and long-term survival independent of the time interval between diagnosis and transplant.

UR - http://www.scopus.com/inward/record.url?scp=85033501864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033501864&partnerID=8YFLogxK

U2 - 10.1002/ajh.24927

DO - 10.1002/ajh.24927

M3 - Article

C2 - 28971503

AN - SCOPUS:85033501864

VL - 93

SP - 40

EP - 46

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -